939983-69-4

Upstream product

• 345-29-9 4-fluorosalicylic acid 
• 75-03-6 ethyl iodide 
• 64-67-5 diethyl sulfate 

Downstream Products

• 1235487-05-4 4-ethanesulfonyl-2-ethoxy-benzoyl chloride 
• 1235486-97-1 2-ethoxy-4-ethylsulfanyl-benzoyl chloride 
• 1235487-16-7 2-ethoxy-4-methanesulfonyl-benzoyl chloride 
• 1233541-55-3 2-ethoxy-4-fluoro-benzoic acid 
• 1444116-26-0 (3-chloro-2,4-dimethyl-7H-pyrrolo[3’4':3,4]pyrazolo[1,5-a]pyrimidin-8(9H)-yl)(4-fluoro-2-hydroxyphenyl)methanone 
• 1445803-75-7 N-{2-[2-(6-chloro-5,7-dimethyl-1H,3H-2,4,7a,8-tetraazacyclopenta[a]indene-2-carbonyl)-5-fluoro-phenoxy]-ethyl}-2,2,2-trifluoro-acetamide 
• 1445803-71-3 {2-[2-(6-chloro-5,7-dimethyl-1H,3H-2,4,7a,8-tetraazacyclopenta[a]indene-2-carbonyl)-5-fluoro-phenoxy]-ethyl}-carbamic acid tert-butyl ester 
• 1445803-68-8 (6-chloro-5,7-dimethyl-1H,3H-2,4,7a,8-tetraaza-cyclopenta[a]inden-2-yl)-[4-fluoro-2-(2-methylamino-propoxy)-phenyl]-methanone 
• 1445803-66-6 (6-chloro-5,7-dimethyl-1H,3H-2,4,7a,8-tetraaza-cyclopenta[a]inden-2-yl)-[2-(2-dimethylamino-propoxy)-4-fluoro-phenyl]-methanone 
• 1445803-62-2 {2-[2-(allyl-methyl-amino)-propoxy]-4-fluoro-phenyl}-(6-chloro-5,7-dimethyl-1H,3H-2,4,7a,8-tetraaza-cyclopenta[a]inden-2-yl)-methanone 
• 1445803-61-1 1-[2-(6-chloro-5,7-dimethyl-1H,3H-2,4,7a,8-tetraazacyclopenta[a]indene-2-carbonyl)-5-fluoro-phenoxy]-propan-2-one 
• 1444116-08-8 (6-chloro-5,7-dimethyl-1H,3H-2,4,7a,8-tetraaza-cyclopenta[a]inden-2-yl)-[2-(2-dimethylamino-ethoxy)-4-fluoro-phenyl]-methanone 
• 1444115-28-9 (6-chloro-5,7-dimethyl-1H,3H-2,4,7a,8-tetraaza-cyclopenta[a]inden-2-yl)-[4-fluoro-2-(2-pyrazol-1-yl-ethoxy)-phenyl]-methanone 
• 1033716-12-9 ethyl 2-ethoxy-4-fluoro-5-nitrobenzoate 

Relevant academic research and scientific papers

GLUCOSE UPTAKE INHIBITORS

this invention provides compounds that modulate glucose uptake activity and cellular transport/uptake of glucose, and particularly GLUTS3, but also including but not limited to GLUT1-14 (SLC2A1-SLC2A14). Compounds of the invention are useful for treating diseases, including cancer, autoimmune diseases and inflammation, infectious diseases, and metabolic diseases.

Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators

The present invention provides compounds of Formula (I) as M1 receptor positive allosteric modulators for the treatment of diseases mediated by the muscarinic M1 mediator.

TETRAAZA-CYCLOPENTA[A]INDENYL AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS

The present invention provides compounds of Formula (I) as M1 receptor positive allosteric modulators for the treatment of diseases mediated by the muscarinic M1 mediator.

QUINOXALINE DERIVATIVE

The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I) in the formula, R1 and R2 each inde